Company Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:55:30 2024-04-16 pm EDT 5-day change 1st Jan Change
1.195 USD -7.36% Intraday chart for Clearside Biomedical, Inc. -6.98% +2.56%

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Number of employees: 30

Sales per Business

USD in Million2022Weight2023Weight Delta
Suprachoroidal Space
100.0 %
1 100.0 % 8 100.0 % +519.89%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 8 100.0 % +519.89%

Managers

Managers TitleAgeSince
Chief Executive Officer 72 17-08-07
Director of Finance/CFO 59 11-12-31
Chief Tech/Sci/R&D Officer - 22-06-13
Chief Tech/Sci/R&D Officer - 13-01-31
Investor Relations Contact - -
Corporate Officer/Principal - 17-12-31
General Counsel - 16-11-30
Corporate Officer/Principal - 16-11-07

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 72 17-08-07
Director/Board Member 64 18-09-25
Director/Board Member 66 11-12-31
Director/Board Member 58 22-03-02
Chairman 57 11-12-31
Director/Board Member 69 16-02-28
Director/Board Member 74 20-04-20
Director/Board Member 55 11-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,721,139 69,367,689 ( 92.84 %) 0 92.84 %

Shareholders

NameEquities%Valuation
6,845,186 9.161 % 10 M $
Hatteras Venture Partners
4.799 %
3,585,562 4.799 % 5 M $
Carmignac Gestion Luxembourg SA (UK)
3.212 %
2,400,344 3.212 % 4 M $
Vanguard Global Advisers LLC
2.913 %
2,176,316 2.913 % 3 M $
Carmignac Gestion SA
2.854 %
2,132,744 2.854 % 3 M $
BlackRock Institutional Trust Co. NA
1.005 %
750,804 1.005 % 1 M $
Geode Capital Management LLC
0.6567 %
490,690 0.6567 % 750 756 $
466,577 0.6244 % 713 863 $
Renaissance Technologies LLC
0.5148 %
384,689 0.5148 % 588 574 $
384,662 0.5148 % 588 533 $

Company contact information

Clearside Biomedical, Inc.

900 North Point Parkway Suite 200

30005, Alpharetta

+678 270 3631

http://www.clearsidebio.com
address Clearside Biomedical, Inc.(CLSD)
  1. Stock Market
  2. Equities
  3. CLSD Stock
  4. Company Clearside Biomedical, Inc.